Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Celgene, NantBioscience in cancer deal

BC Staff
January 15, 2014 2:03 AM UTC

Celgene Corp. (NASDAQ:CELG) partnered with the NantBioscience subsidiary of Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.) to develop a pipeline of cancer drugs using the nanoparticle albumin-bound (nab) technology Celgene gained in its acquisition of Soon-Shiong's former company, Abraxis Bioscience Inc. The deal includes rights to two preclinical compounds-- NTB-011, a nab formulation of a colchicine dimer and NTB-010, a nab formulation of the geldanomycin analogue 17-AAG. NantBioscience plans to start Phase I trials of both by 2015. NantBioscience will receive $75 million from Celgene in an upfront option fee and equity investment. Celgene has an option to license back NTB-011 and NTB-010 through completion of Phase I testing. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article